{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05678205",
            "orgStudyIdInfo": {
                "id": "AB-201-01"
            },
            "organization": {
                "fullName": "Artiva Biotherapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors",
            "officialTitle": "A Multicenter, Open-label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-clinical-trial-of-the-safety-and-anti-tumor-activity-of-ab-in-subjects-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-01",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-23",
            "studyFirstSubmitQcDate": "2022-12-23",
            "studyFirstPostDateStruct": {
                "date": "2023-01-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-05-02",
            "lastUpdatePostDateStruct": {
                "date": "2023-05-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Artiva Biotherapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases. The primary objective of Phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors. The primary objective of Phase 2 is to evaluate the efficacy of AB-201.\n\nSubjects will receive up to 3 doses of AB-201, followed by scheduled assessments of overall health and tumor response."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "Gastric Cancer",
                "Gastroesophageal Junction Adenocarcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 133,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1 Dose Confirmation",
                    "type": "EXPERIMENTAL",
                    "description": "Dose Confirmation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression",
                    "interventionNames": [
                        "Drug: AB-201",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "Phase 2 Cohort A",
                    "type": "EXPERIMENTAL",
                    "description": "AB-201 given to patients with advanced/unresectable or metastatic breast cancer with HER2 overexpression (IHC \u22652+) that is refractory to or intolerant of standard treatment, or for which no standard treatment is available",
                    "interventionNames": [
                        "Drug: AB-201",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "Phase 2 Cohort B",
                    "type": "EXPERIMENTAL",
                    "description": "AB-201 given to patients with advanced/unresectable or metastatic breast cancer with HER2 overexpression (IHC 3+ or IHC 2+/ISH+) that is relapsed to, refractory to, or intolerant of previous trastuzumab deruxtecan (T-DXd) based therapy",
                    "interventionNames": [
                        "Drug: AB-201",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "Phase 2 Cohort C",
                    "type": "EXPERIMENTAL",
                    "description": "AB-201 given to patients with advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression (IHC \u2265 2+) that is refractory to or intolerant of standard treatment, or for which no standard treatment is available",
                    "interventionNames": [
                        "Drug: AB-201",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AB-201",
                    "description": "NK Cell Therapy",
                    "armGroupLabels": [
                        "Phase 1 Dose Confirmation",
                        "Phase 2 Cohort A",
                        "Phase 2 Cohort B",
                        "Phase 2 Cohort C"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Lymphodepleting chemotherapy",
                    "armGroupLabels": [
                        "Phase 1 Dose Confirmation",
                        "Phase 2 Cohort A",
                        "Phase 2 Cohort B",
                        "Phase 2 Cohort C"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Lymphodepleting chemotherapy",
                    "armGroupLabels": [
                        "Phase 1 Dose Confirmation",
                        "Phase 2 Cohort A",
                        "Phase 2 Cohort B",
                        "Phase 2 Cohort C"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety: incidence and severity of adverse events and serious adverse events",
                    "timeFrame": "From the time of consent through End of Study (up to 18 months per patient)"
                },
                {
                    "measure": "Determination of Recommended Phase 2 Dose (RP2D): safety, preliminary efficacy (based on objective response rate (ORR) defined as the proportion of patients with a complete or partial response) and pharmacokinetics",
                    "timeFrame": "From the time of consent through End of Study (up to 18 months per patient)"
                },
                {
                    "measure": "Efficacy: Objective Response Rate, defined as the proportion of patients with a complete or partial response",
                    "timeFrame": "From the time of consent through End of Study (up to 18 months per patient)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* ECOG performance status 0 to 1.\n* Histologically confirmed HER2 expressed breast or gastric/GEJ cancer IHC \u2265 2+ within 6 months prior to study entry.\n* Confirmed diagnosis of an advanced/unresectable or metastatic HER2+ breast or gastric/GEJ cancer that is refractory to, or intolerable of standard treatment, or for which no standard treatment is available.\n* Must have received prior cancer therapy: Subjects with breast cancer must have received \u2265 2 prior systemic therapies; subjects with gastric/GEJ cancer must have received \u2265 1 prior systemic therapy(ies); subjects with IHC 3+ or IHC 2+/ISH+ cancers must have received previous treatment with a HER2-targeting therapy.\n\nExclusion Criteria:\n\n* Known past or current malignancy other than inclusion diagnosis.\n* Known clinically significant cardiac disease.\n* Active central nervous system (CNS) metastases, or involvement of the CNS, unless there is a history of at least 3 months of sustained remission.\n* Unresolved toxicities from prior anticancer therapy.\n* Ongoing uncontrolled systemic infections requiring antibiotic, anti-fungal, or anti-viral therapy.\n* History of sensitivity or intolerance to cyclophosphamide or fludarabine.\n* Pregnant or lactating females and subjects of both sexes who are not willing to practice birth control from the time of consent through 6 months after administration of the last AB-201 dose.\n* Severe disease progression or health deterioration within 2 weeks prior to lymphodepletion regimen.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "AB-201-01 Study Team",
                    "role": "CONTACT",
                    "phone": "858-267-4465",
                    "email": "AB-201-01StudyTeam@ArtivaBio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Thorsten Graef, MD, Ph.D",
                    "affiliation": "Artiva Biotherapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Oregon Health Science University (OHSU)",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Yazan Migdady, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Yazan Migdady, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "The Catholic University of Korea, St. Vincent's Hospital",
                    "city": "Suwon",
                    "state": "Gyeonggi-do",
                    "zip": "16247",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Byoung Y Shim, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Byoung Y Shim, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.29111,
                        "lon": 127.00889
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M325",
                    "name": "Trastuzumab",
                    "relevance": "LOW"
                },
                {
                    "id": "M233243",
                    "name": "Trastuzumab deruxtecan",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}